A detailed history of New York State Common Retirement Fund transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 17,175 shares of FDMT stock, worth $353,461. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,175
Previous 19,422 11.57%
Holding current value
$353,461
Previous $393,000 39.19%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$17.03 - $35.87 $38,266 - $80,599
-2,247 Reduced 11.57%
17,175 $547,000
Q4 2023

Feb 01, 2024

BUY
$9.76 - $21.25 $54,743 - $119,191
5,609 Added 40.61%
19,422 $393,000
Q3 2023

Nov 07, 2023

BUY
$12.64 - $19.76 $2,490 - $3,892
197 Added 1.45%
13,813 $176,000
Q2 2023

Aug 07, 2023

SELL
$15.16 - $23.26 $38,582 - $59,196
-2,545 Reduced 15.75%
13,616 $246,000
Q1 2023

May 02, 2023

SELL
$15.45 - $23.19 $53,657 - $80,538
-3,473 Reduced 17.69%
16,161 $278,000
Q4 2022

Jan 30, 2023

SELL
$6.85 - $25.46 $184 - $687
-27 Reduced 0.14%
19,634 $436,000
Q3 2022

Nov 08, 2022

BUY
$6.96 - $11.48 $69,293 - $114,294
9,956 Added 102.59%
19,661 $158,000
Q2 2022

Aug 04, 2022

SELL
$5.68 - $15.99 $75,197 - $211,691
-13,239 Reduced 57.7%
9,705 $68,000
Q1 2022

May 05, 2022

BUY
$13.16 - $22.64 $112,781 - $194,024
8,570 Added 59.62%
22,944 $347,000
Q4 2021

Feb 02, 2022

BUY
$19.56 - $32.94 $95,433 - $160,714
4,879 Added 51.38%
14,374 $315,000
Q3 2021

Nov 02, 2021

BUY
$22.73 - $36.04 $39,413 - $62,493
1,734 Added 22.34%
9,495 $256,000
Q2 2021

Aug 02, 2021

BUY
$22.2 - $42.29 $94,594 - $180,197
4,261 Added 121.74%
7,761 $187,000
Q1 2021

May 11, 2021

BUY
$35.94 - $52.67 $125,789 - $184,345
3,500 New
3,500 $152,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $666M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.